RegenxBio Inc. and the University of Pennsylvania convinced the Federal Circuit to reinstate a gene-therapy patent a district judge had invalidated as covering natural phenomena, reviving their infringement suit against Sarepta Therapeutics Inc.
https://news.bloomberglaw.com/business-and-practice/tktktktktk-1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.